Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Why Moderna Merged Its Tech and HR Departments
07:00am, Monday, 12'th May 2025
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
07:00am, Thursday, 08'th May 2025
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision
New vaccine chief rocks pharmaceutical stocks
11:13am, Wednesday, 07'th May 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
10:55am, Tuesday, 06'th May 2025
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says
01:53pm, Friday, 02'nd May 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Friday, 02'nd May 2025
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
01:30pm, Thursday, 01'st May 2025
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combinatio
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
01:14pm, Thursday, 01'st May 2025
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
12:26pm, Thursday, 01'st May 2025
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
12:01pm, Thursday, 01'st May 2025
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
08:40am, Thursday, 01'st May 2025
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.
Moderna Posts Loss, Citing Seasonality of Respiratory Business
06:38am, Thursday, 01'st May 2025
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Moderna beats Wall Street estimates for first-quarter profit and sales
06:33am, Thursday, 01'st May 2025
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
06:30am, Thursday, 01'st May 2025
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of
Moderna Earnings Arrive During a Tough Time for the Stock
04:38pm, Wednesday, 30'th Apr 2025
Moderna shares are down more than 30% this year, and around 75% over the past 12 months.
